US11414427B2 - Solid forms of stemospironine and its salts - Google Patents

Solid forms of stemospironine and its salts Download PDF

Info

Publication number
US11414427B2
US11414427B2 US16/646,694 US201816646694A US11414427B2 US 11414427 B2 US11414427 B2 US 11414427B2 US 201816646694 A US201816646694 A US 201816646694A US 11414427 B2 US11414427 B2 US 11414427B2
Authority
US
United States
Prior art keywords
stemospironine
formula
crystalline
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US16/646,694
Other languages
English (en)
Other versions
US20200407368A1 (en
Inventor
Yang Ye
Sheng Yao
Hui-Yin Li
Qun Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US16/646,694 priority Critical patent/US11414427B2/en
Publication of US20200407368A1 publication Critical patent/US20200407368A1/en
Application granted granted Critical
Publication of US11414427B2 publication Critical patent/US11414427B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • This invention relates to certain solid forms of stemospironine and its salts, certain polymorph forms thereof and compositions, methods of their use as therapeutic agents, and methods for their preparation.
  • Stemona alkaloids The roots and rhizomes of the plant family Stemonacae have provided a rich source of structurally novel polycyclic alkaloids referred to as Stemona alkaloids. Initial interest in these substances stemmed from the use of plant materials in herbal teas used in Chinese folk medicine. The use of one such Stemona alkaloid, stemospironine, as an antitussive is disclosed in PCT Patent Publication WO 2009/046635.
  • This invention is directed to stemospironine salts of Formula 1:
  • HX represents hydrogen chloride, hydrogen bromide, L-tartaric acid, D-tartaric acid, sulfuric acid, (+)-(1S)-10-camphorsulfonic acid, ethanesulfonic acid and ethane-1,2-disulfonic acid.
  • XRPD X-ray powder diffraction
  • This invention also provides crystalline polymorph forms of the compound of Formula 1 wherein HX is hydrogen chloride, i.e. stemospironine hydrochloride.
  • HX is hydrogen chloride, i.e. stemospironine hydrochloride.
  • Each polymorph form is characterized by the peaks appearing in its X-ray powder diffraction (XRPD) pattern.
  • This invention also provides a new crystalline form of the compound of Formula 2, i.e. stemospironine free base:
  • the crystalline form is characterized by the peaks appearing in its X-ray powder diffraction (XRPD) pattern.
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising one or more compounds of Formula 1 (i.e. in a therapeutically effective amount) and a pharmaceutically acceptable carrier.
  • This invention further relates to a method of controlling cough, i.e. as an antitussive agent, comprising administering to human a therapeutically effective amount of a compound of Formula 1 (e.g. as a composition described herein).
  • a method of controlling cough i.e. as an antitussive agent, comprising administering to human a therapeutically effective amount of a compound of Formula 1 (e.g. as a composition described herein).
  • This invention also provides methods for the preparation of salts of Formula 1.
  • This invention also provides a method for the preparation of crystalline polymorph forms of Compound 1 wherein X is hydrogen chloride, i.e. stemospironine hydrochloride.
  • This invention also provides a method for the preparation of a crystalline form of a compound of Formula 2, stemospironine free base.
  • FIG. 1 shows a characteristic X-ray powder diffraction pattern of crystalline polymorph Form I of the 1:1 hydrochloric acid salt of stemospironine.
  • FIG. 2 shows a characteristic X-ray powder diffraction pattern of crystalline polymorph Form II of the 1:1 hydrochloric acid salt of stemospironine.
  • FIG. 3 shows a characteristic pattern of crystalline 1:1 hydrobromic acid salt of stemospironine.
  • FIG. 4 shows a characteristic X-ray powder diffraction pattern of crystalline 1:1 L-tartaric acid salt of stemospironine.
  • FIG. 5 shows a characteristic X-ray powder diffraction pattern of crystalline 1:1 D-tartaric acid salt of stemospironine.
  • FIG. 6 shows a characteristic X-ray powder diffraction pattern of crystalline 1:1 sulfuric acid salt of stemospironine.
  • FIG. 7 shows a characteristic X-ray powder diffraction pattern of crystalline 1:1 (+)-(1S)-10-camphorsulfonic acid salt of stemospironine.
  • FIG. 8 shows a characteristic X-ray powder diffraction pattern of crystalline 1:1 ethanesulfonic acid salt of stemospironine.
  • FIG. 9 shows a characteristic X-ray powder diffraction pattern of crystalline 1:1 1,2-ethanedisulfonic acid salt of stemospironine.
  • FIG. 10 shows a characteristic X-ray powder diffraction pattern of crystalline stemospironine.
  • the phrase “pharmaceutically acceptable” refers to those compounds, materials, compositions, carriers and/or dosage forms which are suitable for use in contact with the tissues of human beings and excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
  • the term “effective amount of” refers to an amount of a compound, or a combination of compounds, of the present invention effective when administered alone or in combination as an antitussive agent.
  • crystalline “polymorph” refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice.
  • polymorphs can have the same chemical composition, they can also differ in composition due the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice.
  • Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability.
  • a polymorph can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved solubility, etc.), relative to another polymorph or a mixture of polymorphs of the same compound.
  • Preparation and isolation of a particular polymorph of a compound can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures.
  • Embodiment 1 The salt of Formula I described in the Summary of the Invention in crystalline form.
  • Embodiment 2 The salt of Embodiment 1 wherein HX is hydrogen chloride, in the form of a polymorph Form I that exhibits an X-ray powder diffraction pattern as exemplified in FIG. 1 .
  • Embodiment 3 The salt of Embodiment 1 wherein HX is hydrogen chloride, in the form of a polymorph Form I that exhibits an X-ray powder diffraction pattern having characteristic peaks, expressed in degrees 2 ⁇ , as shown in Table 1.
  • Embodiment 4 The salt of Embodiment 1 wherein HX is hydrogen chloride, in the form of a polymorph Form II that exhibits an X-ray powder diffraction pattern as exemplified in FIG. 2 .
  • Embodiment 5 The salt of Embodiment 1 wherein HX is hydrogen chloride, in the form of a polymorph Form II that exhibits an X-ray powder diffraction pattern having characteristic peaks, expressed in degrees 2 ⁇ , as shown in Table 2.
  • Embodiment 6 The salt of Embodiment 1 wherein HX is hydrogen bromide, that exhibits an X-ray powder diffraction pattern as exemplified in FIG. 3 .
  • Embodiment 7 The salt of Embodiment 1 wherein HX is hydrogen bromide, that exhibits an X-ray powder diffraction pattern having characteristic peaks, expressed in degrees 2 ⁇ , as shown in Table 3.
  • Embodiment 8 The salt of Embodiment 1 wherein HX is L-tartaric acid, that exhibits an X-ray powder diffraction pattern as exemplified in FIG. 4 .
  • Embodiment 9 The salt of Embodiment 1 wherein HX is L-tartaric acid, that exhibits an X-ray powder diffraction pattern having characteristic peaks, expressed in degrees 2 ⁇ , as shown in Table 4.
  • Embodiment 10 The salt of Embodiment 1 wherein HX is D-tartaric acid that exhibits an X-ray powder diffraction pattern as exemplified in FIG. 5 .
  • Embodiment 11 The salt of Embodiment 1 wherein HX is D-tartaric acid that exhibits an X-ray powder diffraction pattern having characteristic peaks, expressed in degrees 2 ⁇ , as shown in Table 5.
  • Embodiment 12 The salt of Embodiment 1 wherein HX is sulfuric acid, that exhibits an X-ray powder diffraction pattern as exemplified in FIG. 6 .
  • Embodiment 13 The salt of Embodiment 1 wherein HX is sulfuric acid, that exhibits an X-ray powder diffraction pattern having characteristic peaks, expressed in degrees 2 ⁇ , as shown in Table 6.
  • Embodiment 14 The salt of Embodiment 1 wherein HX is (+)-(1S)-10-camphorsulfonic acid, that exhibits an X-ray powder diffraction pattern as exemplified in FIG. 7 .
  • Embodiment 15 The salt of Embodiment 1 wherein HX is (+)-(1S)-10-camphorsulfonic acid, that exhibits an X-ray powder diffraction pattern having characteristic peaks, expressed in degrees 2 ⁇ , as shown in Table 7.
  • Embodiment 16 The salt of Embodiment 1 wherein HX is ethanesulfonic acid, that exhibits an X-ray powder diffraction pattern as exemplified in FIG. 8 .
  • Embodiment 17 The salt of Embodiment 1 wherein HX is ethanesulfonic acid, that exhibits an X-ray powder diffraction pattern having characteristic peaks, expressed in degrees 2 ⁇ , as shown in Table 8.
  • Embodiment 18 The salt of Embodiment 1 wherein HX is 1,2-ethanedisulfonic acid, that exhibits an X-ray powder diffraction pattern as exemplified in FIG. 9 .
  • Embodiment 17 The salt of Embodiment 1 wherein HX is 1,2-ethanedisulfonic acid, that exhibits an X-ray powder diffraction pattern having characteristic peaks, expressed in degrees 2 ⁇ , as shown in Table 9.
  • Embodiment 18 A crystalline form of the compound of Formula 2, i.e. stemospironine free base, that exhibits an X-ray powder diffraction pattern as exemplified in FIG. 10 .
  • Embodiment 19 A crystalline form of the compound of Formula 2, i.e. stemospironine free base, that exhibits an X-ray powder diffraction pattern having characteristic peaks, expressed in degrees 2 ⁇ , as shown in Table 10.
  • compositions comprising one or more compounds of Formula 1 and a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier comprising one or more compounds of Formula 1 and a pharmaceutically acceptable carrier.
  • This invention provides a method of controlling cough comprising administering to a human a therapeutically effective amount of a compound of Formula 1.
  • methods comprising applying a therapeutically effective amount of a compound corresponding to any of the embodiments described above.
  • embodiments where compounds are administered orally are also of particular note.
  • the present invention further discloses a method for preparing crystalline stemosporinine salts of Formula 1 from stemosporinine, a compound of Formula 2, and an acid HX, comprising:
  • the first and second solvents are independently selected from the group consisting of water, methanol, ethanol, isopropanol and acetonitrile.
  • the third solvent is independently selected from the group consisting of methyl tert-butyl ether, heptane and hexane.
  • the acid HX is selected from the group consisting of hydrogen chloride, hydrogen bromide, L-tartaric acid, D-tartaric acid, sulfuric acid, (+)-(1S)-10-camphorsulfonic acid, ethanesulfonic acid and ethane-1,2-disulfonic acid.
  • the present invention further discloses a method for preparing crystalline stemospironne hydrochloride polymorph Form II comprising:
  • the polymorph salts of the present invention may be in a non-solvated form or a solvated form, in particular in a hydrated form or an alcoholated form.
  • polymorph salts of the present invention i.e. a compound of Formula 1 wherein HX is hydrogen chloride
  • HX hydrogen chloride
  • Polymorph forms of the present invention are characterized by the peaks appearing in the X-ray powder diffraction (XRPD) pattern.
  • the XRPD patterns of the polymorphs of this invention were measured by a Rigaku Miniflex X-ray Powder Diffractometer (XRPD) instrument.
  • X-ray radiation is from Copper Cu at 1.054056 ⁇ with K ⁇ filter.
  • X-ray power is 30 KV, 15 mA.
  • Sample powder is dispersed on a zero-background sample holder.
  • General measurement conditions are: start angle ⁇ 3; stop angle ⁇ 45; scan speed ⁇ 2 deg/min.
  • FIG. 1 shows a characteristic X-ray powder diffraction (XRPD) pattern of polymorph Form 1 of the 1:1 hydrochloric acid salt of stemospironine. Characteristic peaks, expressed in degrees 2 ⁇ , are listed in Table 1.
  • FIG. 2 shows a characteristic X-ray powder diffraction (XRPD) pattern of polymorph Form II of the 1:1 hydrochloric acid salt of stemosporinine. Characteristic peaks, expressed in degrees 2 ⁇ , are listed in Table 2.
  • FIG. 3 shows a characteristic X-ray powder diffraction (XRPD) pattern of stemospironine monohydrobromide. Characteristic peaks, expressed in degrees 2 ⁇ , are listed in Table 3.
  • FIG. 4 shows a characteristic X-ray powder diffraction (XRPD) pattern of the 1:1 L-tartaric acid salt of stemospironine. Characteristic peaks, expressed in degrees 2 ⁇ , are listed in Table 4.
  • FIG. 5 shows a characteristic X-ray powder diffraction (XRPD) pattern of the 1:1 D-tartaric acid salt of stemospironine. Characteristic peaks, expressed in degrees 2 ⁇ , are listed in Table 5.
  • FIG. 6 shows a characteristic X-ray powder diffraction (XRPD) pattern of the 1:1 sulfuric acid salt of stemospironine. Characteristic peaks, expressed in degrees 2 ⁇ , are listed in Table 6.
  • FIG. 7 shows a characteristic X-ray powder diffraction (XRPD) pattern of the 1:1 (+)-(1S)-10-camphorsulfonic acid salt of stemospironine. Characteristic peaks, expressed in degrees 2 ⁇ , are listed in Table 7.
  • FIG. 8 shows a characteristic X-ray powder diffraction (XRPD) pattern of the 1:1 ethanesulfonic acid salt of stemospironine. Characteristic peaks, expressed in degrees 2 ⁇ , are listed in Table 8.
  • FIG. 9 shows a characteristic X-ray powder diffraction (XRPD) pattern of the 1:1 1,2-ethanedisulfonic acid salt of stemospironine. Characteristic peaks, expressed in degrees 2 ⁇ , are listed in Table 9.
  • FIG. 10 shows a characteristic X-ray powder diffraction (XRPD) pattern of crystalline stemosporinine. Characteristic peaks, expressed in degrees 2 ⁇ , are listed in Table 10.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
US16/646,694 2017-09-12 2018-09-07 Solid forms of stemospironine and its salts Active US11414427B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/646,694 US11414427B2 (en) 2017-09-12 2018-09-07 Solid forms of stemospironine and its salts

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762606161P 2017-09-12 2017-09-12
PCT/US2018/049851 WO2019055294A1 (en) 2017-09-12 2018-09-07 SOLID FORMS OF STEEMOSPIRONIN AND ITS SALTS
US16/646,694 US11414427B2 (en) 2017-09-12 2018-09-07 Solid forms of stemospironine and its salts

Publications (2)

Publication Number Publication Date
US20200407368A1 US20200407368A1 (en) 2020-12-31
US11414427B2 true US11414427B2 (en) 2022-08-16

Family

ID=65723426

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/646,694 Active US11414427B2 (en) 2017-09-12 2018-09-07 Solid forms of stemospironine and its salts

Country Status (7)

Country Link
US (1) US11414427B2 (ko)
EP (1) EP3681506A4 (ko)
JP (1) JP2020536951A (ko)
KR (1) KR20200068667A (ko)
CN (1) CN111565723A (ko)
CA (1) CA3075740A1 (ko)
WO (1) WO2019055294A1 (ko)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229071A1 (en) * 2002-04-24 2003-12-11 The Chinese University Of Hong Kong Plant extracts and alkaloids having antitussive activity
US20070060564A1 (en) * 2005-09-12 2007-03-15 But Pui-Hay P Method of making antitussive medicine and relieving cough
WO2009046635A1 (fr) 2007-09-28 2009-04-16 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Utilisation d'alcaloïdes dans la préparation de médicaments traitant la toux
US20090176818A1 (en) 2005-12-21 2009-07-09 Toray Industries, Inc. Antitussive Agent
CN104138381A (zh) 2014-07-30 2014-11-12 中国药科大学 一种螺环生物碱在制备预防或治疗肺纤维化药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1526135A1 (en) * 2003-10-24 2005-04-27 Warner-Lambert Company LLC Azabenzodiazepines as pde4 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229071A1 (en) * 2002-04-24 2003-12-11 The Chinese University Of Hong Kong Plant extracts and alkaloids having antitussive activity
US20070060564A1 (en) * 2005-09-12 2007-03-15 But Pui-Hay P Method of making antitussive medicine and relieving cough
US20090176818A1 (en) 2005-12-21 2009-07-09 Toray Industries, Inc. Antitussive Agent
WO2009046635A1 (fr) 2007-09-28 2009-04-16 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Utilisation d'alcaloïdes dans la préparation de médicaments traitant la toux
CN104138381A (zh) 2014-07-30 2014-11-12 中国药科大学 一种螺环生物碱在制备预防或治疗肺纤维化药物中的应用

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Bardaji, Org. Lett., vol. 14, No. 18, 2012, 4854-4857. *
Bastin et al., "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities", Organic Process Research & Development, 2000, vol. 4, pp. 427-435.
Extended European Search Report dated Aug. 24, 2021, in corresponding European Patent Application No. 18856013.0.
Fukaya et al., "Absolute Structures of Stemona-Lactam S and Tuberostemospiroline, Alkaloids from Stemona tuberosa", Chem. Pharm. Bull., 2013, vol. 61, No. 10, pp. 1085-1089.
International Search Report dated Oct. 24, 2018 in International (PCT) Application No. PCT/US18/49851.
Lindsay, K. B., "The asymmetric synthesis of polyfunctional pyrrolidine alkaloids and their analogues", University of Wollongong Theses Collection, University of Wollongong, 2003, pp. 1-75, 94 total pages.
Mino R. Caira, "Crystalline Polymorphism of Organic Compounds", Topics in Current Chemistry, 1998, vol. 198, pp. 163-208.
Partial Supplementary European Search Report dated Apr. 14, 2021 in corresponding European Patent Application No. 18856013.0.
Pilli et al., "The chemistry of Stemona alkaloids: An update", Nat. Prod. Rep., 2010, vol. 27, pp. 1908-1937.
Sakata et al., "Stemospironine, a New Insecticidal Alkaloid of Stemona japonica Miq. Isolation, Structural Determination and Activity", Agric. Biol. Chem., 1978, vol. 42, No. 2, pp. 457-463.
Sakata, Agricultural and Biological Chemistry (1978), 42(2), 457-63. *
Suzuki, Yakugaku Zasshi (1931), 51, 419-29. *
Suzuki, Yakugaku Zasshi (1934)54, 561-6, Abstracts 101-4. *
Wiedmann, Asian journal of pharmaceutical sciences 11 (2016) 722-734. *
Ye et al., "Alkaloids of Stemona japonica", Phytochemistry, 1994, vol. 37, No. 4, pp. 1205-1208.

Also Published As

Publication number Publication date
EP3681506A1 (en) 2020-07-22
CN111565723A (zh) 2020-08-21
WO2019055294A1 (en) 2019-03-21
JP2020536951A (ja) 2020-12-17
CA3075740A1 (en) 2019-03-21
EP3681506A4 (en) 2021-09-22
KR20200068667A (ko) 2020-06-15
US20200407368A1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
EP2909191B1 (en) Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
US10351574B2 (en) Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
US20160015706A1 (en) Crystalline forms of an antidepressant compound
CN114276290A (zh) 一种雷芬那辛无水晶型及其制备方法
US20140163083A1 (en) Novel crystalline salts of asenapine
JP2012515141A (ja) イバブラジン硫酸塩及びそのｉ型結晶の製造方法
TW200900392A (en) Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same
US20220002302A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
US11414427B2 (en) Solid forms of stemospironine and its salts
US20140128444A1 (en) Novel crystalline salts of asenapine with organic di-acids and tri-acids
US10519150B2 (en) Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof
US7534888B2 (en) Oxycodone polymorphs
JP5336509B2 (ja) （ｒ）−３−フルオロフェニル−３，４，５−トリフルオロベンジルカルバミン酸１−アザビシクロ［２．２．２］オクト−３−イルエステルの安定な結晶性塩
US20200283381A1 (en) Solid state forms of elafibranor
EP2085397A1 (en) Crystalline form of abacavir
US8399475B2 (en) Crystalline and amorphous forms of naltrexone hydrochloride
WO2011027324A1 (en) Polymorphic forms of atazanavir sulfate
US10894768B2 (en) Salt of (R)-(1-methylpyrrolidine-3-yl)methyl(3′-chloro-4′-fluoro-[1,1′-biphenyl]-2-yl)carbamate and crystal form thereof
US10155740B2 (en) Crystal forms of immunomodulatory drug pomalidomide and co-crystal with gentisic acid
US11384073B2 (en) Maleate salt of benzothiophene compound, crystalline form thereof, and use thereof
WO2017195086A1 (en) Salts of n,n-dimethylbiguanide and preparation methods thereof
BR102021023325A2 (pt) Método de obtenção de duas novas formas cristalinas de adifenina, seus sais oxalato e citrato, formulações farmacêuticas e seus usos
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
US20100324078A1 (en) Crystalline Forms of Naltrexone Methobromide
EP3210975A1 (en) Cocrystals of lorcaserin

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE